Drug Profile
Research programme: cancer therapeutics and antibiotics - Sanofi/Warp Drive Bio
Alternative Names: RAS gene inhibitors - Sanofi/Warp Drive BioLatest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator Warp Drive Bio
- Developer Sanofi; Warp Drive Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action Ras gene inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Gram-negative infections
Most Recent Events
- 30 Dec 2022 Discontinued for Cancer in USA (unspecified route)
- 30 Dec 2022 Discontinued for Gram-negative infections in USA (unspecified route)
- 28 Feb 2020 No recent reports of development identified for research development in Gram-negative-infections in USA